4.6 Review

Strategies for Glycoengineering Therapeutic Proteins

期刊

FRONTIERS IN CHEMISTRY
卷 10, 期 -, 页码 -

出版社

FRONTIERS MEDIA SA
DOI: 10.3389/fchem.2022.863118

关键词

glycoengineering; pharmacodynamics; pharmacokinetics; therapeutic; glycosylation; N-glycans; biomanufacturing

资金

  1. National Institutes of Health [R01EB029455, R01CA240339, R21CA249381, R01CA112314]
  2. Cohen Translation Fund (JHU)

向作者/读者索取更多资源

This article discusses the important role of glycosylation in therapeutic proteins and provides examples of drugs that have been improved through glycoengineering. As glycoengineering strategies develop, deliberate modification of therapeutic protein glycosylation will become more prevalent.
Almost all therapeutic proteins are glycosylated, with the carbohydrate component playing a long-established, substantial role in the safety and pharmacokinetic properties of this dominant category of drugs. In the past few years and moving forward, glycosylation is increasingly being implicated in the pharmacodynamics and therapeutic efficacy of therapeutic proteins. This article provides illustrative examples of drugs that have already been improved through glycoengineering including cytokines exemplified by erythropoietin (EPO), enzymes (ectonucleotide pyrophosphatase 1, ENPP1), and IgG antibodies (e.g., afucosylated Gazyva (R), Poteligeo (R), Fasenra (TM), and Uplizna (R)). In the future, the deliberate modification of therapeutic protein glycosylation will become more prevalent as glycoengineering strategies, including sophisticated computer-aided tools for building in glycans sites, acceptance of a broad range of production systems with various glycosylation capabilities, and supplementation methods for introducing non-natural metabolites into glycosylation pathways further develop and become more accessible.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据